Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
ACS Appl Mater Interfaces ; 8(1): 350-62, 2016 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-26646711

RESUMEN

We have developed PEGylated mesoporous carbon nanocapsule as a universal nanoreactor and carrier for the delivery of highly crystalline hydrophobic/hydrophilic nanoparticles (NPs) which shows superior biocompatibility, dispersion in body fluids, good biodistribution and NPs independent cellular uptake mechanism. The hydrophobic/hydrophilic NPs without surface modification were synthesized in situ inside the cavities of mesoporous carbon capsules (200-850 nm). Stable and inert nature of carbon capsules in a wide range of reaction conditions like high temperature and harsh solvents, make it suitable for being used as nano/microreactors for the syntheses of a variety of NPs for bioimaging applications, such as NaYF4:Eu(3+)(5%), LaVO4:Eu(3+)(10%), GdVO4:Eu(3+)(10%), Y2O3:Eu(3+)(5%), GdF3:Tb(3+)(10%), Mo, Pt, Pd, Au, and Ag. Multiple types of NPs (Y2O3:Eu(3+)(5%) (hydrophobic) and GdF3:Tb(3+)(10%) (hydrophilic)) were coloaded inside the carbon capsules to create a multimodal agent for magneto-fluorescence imaging. Our in vivo study clearly suggests that carbon capsules have biodistribution in many organs including liver, heart, spleen, lungs, blood pool, and muscles.


Asunto(s)
Portadores de Fármacos/química , Interacciones Hidrofóbicas e Hidrofílicas , Nanocápsulas/química , Polietilenglicoles/química , Animales , Materiales Biocompatibles/farmacología , Carbono , Línea Celular Tumoral , Endocitosis/efectos de los fármacos , Fluorescencia , Humanos , Ratones Endogámicos C57BL , Nanocápsulas/ultraestructura , Nanopartículas/química , Tamaño de la Partícula , Polietilenglicoles/farmacocinética , Propiedades de Superficie , Distribución Tisular/efectos de los fármacos , Difracción de Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...